Brief News: InSilico Medicine Cayman TopCo's Hong Kong Stock IPO has been filed with the China Securities Regulatory Commission
I'm PortAI, I can summarize articles.
InSilico Medicine Cayman TopCo has received approval from Chinese securities regulators to list in Hong Kong, planning to sell up to 108 million shares. The company has previously applied for listing multiple times without success and applied again in November this year. In the first half of this year, InSilico Medicine reported a loss of $19.215 million, with revenue declining by 54% year-on-year. Its AI platform Pharma.AI has generated over 20 clinical or IND-stage assets, with a wide range of applications
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: BambooWorks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments